International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation; 2021.
Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183: 109119. https://doi.org/10.1016/j.diabres.2021.109119.
Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068–83. https://doi.org/10.1016/s0140-6736(13)62154-6.
CAS Article PubMed Google Scholar
McCarthy MI. Painting a new picture of personalised medicine for diabetes. Diabetologia. 2017;60:793–9. https://doi.org/10.1007/s00125-017-4210-x.
Article PubMed PubMed Central Google Scholar
Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361–9. https://doi.org/10.1016/s2213-8587(18)30051-2.
Ahlqvist E, Prasad RB, Groop L. Subtypes of type 2 diabetes determined from clinical parameters. Diabetes. 2020;69:2086–93. https://doi.org/10.2337/dbi20-0001.
CAS Article PubMed Google Scholar
Udler MS, Kim J, von Grotthuss M, Bonàs-Guarch S, Cole JB, Chiou J, et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med. 2018;15: e1002654. https://doi.org/10.1371/journal.pmed.1002654.
CAS Article PubMed PubMed Central Google Scholar
Mahajan A, Wessel J, Willems SM, Zhao W, Robertson NR, Chu AY, et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat Genet. 2018;50:559–71. https://doi.org/10.1038/s41588-018-0084-1.
CAS Article PubMed PubMed Central Google Scholar
DiCorpo D, LeClair J, Cole JB, Sarnowski C, Ahmadizar F, Bielak LF, et al. Type 2 diabetes partitioned polygenic scores associate with disease outcomes in 454,193 individuals across 13 cohorts. Diabetes Care. 2022;45:674–83. https://doi.org/10.2337/dc21-1395.
CAS Article PubMed PubMed Central Google Scholar
Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat Genet. 2022;54:560–72. https://doi.org/10.1038/s41588-022-01058-3.
CAS Article PubMed Google Scholar
Vujkovic M, Keaton JM, Lynch JA, Miller DR, Zhou J, Tcheandjieu C, et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat Genet. 2020;52:680–91. https://doi.org/10.1038/s41588-020-0637-y.
CAS Article PubMed PubMed Central Google Scholar
Chen J, Spracklen CN, Marenne G, Varshney A, Corbin LJ, Luan J, et al. The trans-ancestral genomic architecture of glycemic traits. Nat Genet. 2021;53:840–60. https://doi.org/10.1038/s41588-021-00852-9.
CAS Article PubMed PubMed Central Google Scholar
Florez JC. Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia. 2008;51:1100–10. https://doi.org/10.1007/s00125-008-1025-9.
CAS Article PubMed Google Scholar
Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320–3. https://doi.org/10.1038/ng1732.
CAS Article PubMed Google Scholar
Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest. 2007;117:2155–63. https://doi.org/10.1172/jci30706.
CAS Article PubMed PubMed Central Google Scholar
da Silva XG, Loder MK, McDonald A, Tarasov AI, Carzaniga R, Kronenberger K, et al. TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells. Diabetes. 2009;58:894–905. https://doi.org/10.2337/db08-1187.
Srinivasan S, Kaur V, Chamarthi B, Littleton KR, Chen L, Manning AK, et al. TCF7L2 genetic variation augments incretin resistance and influences response to a sulfonylurea and metformin: the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). Diabetes Care. 2018;41:554–61. https://doi.org/10.2337/dc17-1386.
CAS Article PubMed PubMed Central Google Scholar
Udler MS, McCarthy MI, Florez JC, Mahajan A. Genetic risk scores for diabetes diagnosis and precision medicine. Endocr Rev. 2019;40:1500–20. https://doi.org/10.1210/er.2019-00088.
Article PubMed PubMed Central Google Scholar
Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, et al. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the Diabetes Prevention Program. Diabetes. 2011;60:1340–8. https://doi.org/10.2337/db10-1119.
CAS Article PubMed PubMed Central Google Scholar
Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50:1219–24. https://doi.org/10.1038/s41588-018-0183-z.
CAS Article PubMed PubMed Central Google Scholar
Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet. 2018;50:1505–13. https://doi.org/10.1038/s41588-018-0241-6.
CAS Article PubMed PubMed Central Google Scholar
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Management of hyperglycaemia in type 2 diabetes, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;2018(61):2461–98. https://doi.org/10.1007/s00125-018-4729-5.
Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36:2254–61. https://doi.org/10.2337/dc13-0356.
CAS Article PubMed PubMed Central Google Scholar
Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355:467–77. https://doi.org/10.1056/NEJMoa061759.
CAS Article PubMed Google Scholar
Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 2014;311:279–86. https://doi.org/10.1001/jama.2013.283980.
CAS Article PubMed Google Scholar
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–43. https://doi.org/10.1056/NEJMoa066224.
CAS Article PubMed Google Scholar
Pavkov ME, Hanson RL, Knowler WC, Bennett PH, Krakoff J, Nelson RG. Changing patterns of type 2 diabetes incidence among Pima Indians. Diabetes Care. 2007;30:1758–63. https://doi.org/10.2337/dc06-2010.
Zhou K, Donnelly L, Yang J, Li M, Deshmukh H, Van Zuydam N, et al. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol. 2014;2:481–7. https://doi.org/10.1016/s2213-8587(14)70050-6.
CAS Article PubMed PubMed Central Google Scholar
Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81–98. https://doi.org/10.2165/11534750-000000000-00000.
CAS Article PubMed Google Scholar
Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E, et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics. 2002;12:591–5. https://doi.org/10.1097/00008571-200211000-00002.
CAS Article PubMed Google Scholar
Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117:1422–31. https://doi.org/10.1172/jci30558.
CAS Article PubMed PubMed Central Google Scholar
Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney ASF, Leese G, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009;58:1434–9. https://doi.org/10.2337/db08-0896.
CAS Article PubMed PubMed Central Google Scholar
Christensen MMH, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011;21:837–50. https://doi.org/10.1097/FPC.0b013e32834c0010.
CAS Article PubMed Google Scholar
Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes. 2015;64:1786–93. https://doi.org/10.2337/db14-1388.
留言 (0)